Cancer Genetics (NASDAQ:CGIX) was downgraded by ValuEngine from a “sell” rating to a “strong sell” rating in a report released on Friday.

A number of other analysts also recently issued reports on CGIX. HC Wainwright set a $6.00 target price on Cancer Genetics and gave the stock a “buy” rating in a research report on Tuesday, August 15th. Zacks Investment Research downgraded Cancer Genetics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. Cancer Genetics presently has an average rating of “Hold” and a consensus target price of $5.42.

Cancer Genetics (NASDAQ CGIX) traded up $0.07 during trading hours on Friday, reaching $2.45. The company’s stock had a trading volume of 55,763 shares, compared to its average volume of 241,467. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.01 and a quick ratio of 2.01. Cancer Genetics has a twelve month low of $1.30 and a twelve month high of $5.30.

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Cancer Genetics by 61.9% in the second quarter. Vanguard Group Inc. now owns 516,785 shares of the medical research company’s stock worth $2,041,000 after buying an additional 197,619 shares during the last quarter. Renaissance Technologies LLC increased its position in Cancer Genetics by 44.8% in the first quarter. Renaissance Technologies LLC now owns 449,600 shares of the medical research company’s stock worth $1,843,000 after buying an additional 139,200 shares during the last quarter. Granahan Investment Management Inc. MA increased its position in Cancer Genetics by 26.3% in the third quarter. Granahan Investment Management Inc. MA now owns 237,431 shares of the medical research company’s stock worth $641,000 after buying an additional 49,371 shares during the last quarter. Thompson Davis & CO. Inc. increased its position in Cancer Genetics by 5,465.0% in the second quarter. Thompson Davis & CO. Inc. now owns 111,300 shares of the medical research company’s stock worth $440,000 after buying an additional 109,300 shares during the last quarter. Finally, Northern Trust Corp increased its position in Cancer Genetics by 61.0% in the second quarter. Northern Trust Corp now owns 32,122 shares of the medical research company’s stock worth $127,000 after buying an additional 12,168 shares during the last quarter. 12.71% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This piece was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/02/valuengine-downgrades-cancer-genetics-cgix-to-strong-sell.html.

About Cancer Genetics

Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.

Receive News & Stock Ratings for Cancer Genetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics Inc and related stocks with our FREE daily email newsletter.